Tag: Pharma
MaaT Pharma announces the implementation of the liquidity contract with Kepler Cheuvreux – 03/21/2022 at 18:21
Lyon, France, March 21, 2022 – 6:00 p.m. CET – MaaT Pharma (EURONEXT: “MAAT” – the Company), a French late-stage biotechnology company, a pioneer in the development of drugs for…
MaaT Pharma to present promising clinical data for MaaT013, its most advanced drug candidate, at the 48th annual meeting of the EBMT – 03/17/2022 at 18:15
MaaT Pharma announces today that promising results from its Phase 2 clinical trial HERACLES (n=24) and its compassionate access program (n=52) for its most advanced microbiota drug candidate, MaaT013, will…
Eurazeo: the Nov Santé Actions Non Cotées fund invests in Horus Pharma – 03/15/2022 at 09:53
(AOF) – The Nov Santé Actions Non Cotées fund, managed by Eurazeo, dedicated to the development of healthcare sectors in France and launched at the initiative of France Assureurs and…
Eurazeo: investment of a fund in Horus Pharma
(CercleFinance.com) – Eurazeo indicates that its managed fund Nov Santé Actions Non Cotées, dedicated to the development of the health sectors in France and launched at the initiative of France…
Pherecydes Pharma: obtains a second patent in China
(CercleFinance.com) – Pherecydes Pharma announces that the Chinese patent office has granted it a patent for its anti-Pseudomonas aeruginosa phages – Pseudomonas aeruginosa being one of the six deadliest germs.…
MaaT Pharma and Skyepharma announce their partnership to launch the first French production plant exclusively dedicated to biotherapies derived from the microbiota – 02/08/2022 at 18:28
MaaT Pharma, a French biotechnology company in advanced clinical stage (Phase 3), a pioneer in the development of drugs in the restoration of the intestinal microbiota to improve the survival…
Pherecydes Pharma: green light from the CPP for a clinical study – 02/07/2022 at 18:19
(CercleFinance.com) – Pherecydes Pharma announces today that it has received the positive opinion of the Ile de France III Committee for the Protection of Persons (CPP) for the PhagoDAIR study,…
Pherecydes Pharma: green light from the CPP for a clinical study
(CercleFinance.com) – Pherecydes Pharma announces today that it has received the positive opinion of the Ile de France III Committee for the Protection of Persons (CPP) for the PhagoDAIR study,…
Pherecydes Pharma: receives the positive opinion of the Committee for the Protection of Persons to initiate the PhagoDAIR study
Pherecydes Pharma receives the positive opinion of the Committee for the Protection of People to initiate the PhagoDAIR study PhagoDAIR is a…
NOXXON Pharma: new issue of convertible bonds for 2.375 ME
OC Published on 01/28/2022 at 6:10 p.m. Photo credit © Reuters …
Noxxon Pharma: financing of 2.37 million euros as part of the agreement with Atlas – 01/28/2022 at 18:08
(AOF) – Noxxon Pharma announced on Friday evening that it had drawn additional tranches of financing from its financing agreement with Atlas Special Opportunities, LLC (ASO), for a total amount…
Maat Pharma, its MaaT033 treatment induces good colonization of the microbiota
The title of bioteh is however down on the stock market. The company hopes to quickly move from phase 1b to phase 2/3. Maat Pharma, its MaaT033 treatment induces good…